{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:39:28Z","timestamp":1791913168692,"version":"4.3.4"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"\n Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in deficient treatment responses. Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy and clinical populations. The main aim of the present study was investigation of the effects of psilocybin-containing truffles, when taken in a supportive group setting, on ratings of state and trait anxiety across self-reported healthy volunteers. Attendees of psilocybin ceremonies were asked to complete a test battery at three separate occasions: before the ceremony (baseline), the morning after, and 1 week after the ceremony. The test battery included questionnaires assessing state and trait anxiety (State-Trait Anxiety Inventory), mindfulness capacities (Five Facet Mindfulness Questionnaire), and personality (Big Five Inventory). Additionally, the psychedelic experience was quantified with the Persisting Effects Questionnaire and the Ego Dissolution Inventory. The total amount of psilocybin-containing truffles consumed by each participant was recorded, and a sample of the truffles was analyzed to determine psilocin concentrations. Fifty-two attendees (males = 25; females = 25; others = 2) completed parts of the baseline assessment, 46 (males = 21; females = 24; others = 1) completed assessments the morning after the ceremony, and 23 (males = 10; females = 13) completed assessments at the 1-week follow-up. Average psilocin consumption across individuals was 27.1 mg. The morning after the ceremony, we observed medium reductions in anxiety measures (both state and trait) compared to baseline (\n \n \n \n d<\/mml:mi>\n \u00af<\/mml:mo>\n <\/mml:munder>\n <\/mml:math>\n <\/jats:inline-formula>\n = 6.4;\n p<\/jats:italic>\n &lt; 0.001 and\n \n \n \n d<\/mml:mi>\n \u00af<\/mml:mo>\n <\/mml:munder>\n <\/mml:math>\n <\/jats:inline-formula>\n = 6;\n p<\/jats:italic>\n = 0.014, respectively), which persisted over a 1-week period post-ceremony (\n \n \n \n d<\/mml:mi>\n \u00af<\/mml:mo>\n <\/mml:munder>\n <\/mml:math>\n <\/jats:inline-formula>\n = 6.7;\n p<\/jats:italic>\n = 0.001 and\n \n \n \n d<\/mml:mi>\n \u00af<\/mml:mo>\n <\/mml:munder>\n <\/mml:math>\n <\/jats:inline-formula>\n = 8.6;\n p<\/jats:italic>\n = 0.004, respectively). At 1 week post-ceremony, the non-judging facet of the mindfulness scale was increased (\n \n \n \n d<\/mml:mi>\n \u00af<\/mml:mo>\n <\/mml:munder>\n <\/mml:math>\n <\/jats:inline-formula>\n = 1.5;\n p<\/jats:italic>\n = 0.03), while the personality trait neuroticism decreased (\n \n \n \n d<\/mml:mi>\n \u00af<\/mml:mo>\n <\/mml:munder>\n <\/mml:math>\n <\/jats:inline-formula>\n = 5.2;\n p<\/jats:italic>\n = 0.005), when compared to baseline. Additionally, we found ratings of ego dissolution (mean: 59.7, SD: 28.3) and changes in neuroticism to be the strongest predictors of reductions in state and trait anxiety, respectively. In sum, results suggest rapid and persisting (up to 1 week) anxiolytic effects in individuals with sub-clinical anxiety symptoms, which are related to the acute experience of ego dissolution, as well as lasting changes in trait neuroticism. Results also add support to the feasibility and potential efficacy of group sessions with psychedelics. To understand whether these effects extend to wider populations suffering from heightened anxiety, and the mechanisms involved, further experimental research is needed.\n <\/jats:p>","DOI":"10.3389\/fpsyt.2022.883869","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:46:38Z","timestamp":1657154798000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees"],"prefix":"10.3389","volume":"13","author":[{"given":"Maggie Kamila","family":"Kiraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim P. C.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin Vedoy","family":"Uthaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes G.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Leigh","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"B1","first-page":"16","article-title":"Psychiatric disorders: a global look at facts and figures.","volume":"7","author":"Sansone","year":"2010","journal-title":"Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.31887\/DCNS.2017.19.2\/dstein","article-title":"Epidemiology of anxiety disorders: from surveys to nosology and back.","volume":"19","author":"Stein","year":"2017","journal-title":"Dialogues Clin Neurosci."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-018-0923-x","article-title":"Moving to beat anxiety: epidemiology and therapeutic issues with physical activity for anxiety.","volume":"20","author":"Kandola","year":"2018","journal-title":"Curr Psychiatry Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.2174\/138161208786848810","article-title":"Room for improvement in the pharmacological treatment of anxiety disorders.","volume":"14","author":"Baldwin","year":"2008","journal-title":"Curr Pharm Des."},{"key":"B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1468-2850.2010.01198.x","article-title":"Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes.","volume":"17","author":"Otto","year":"2010","journal-title":"Clin Psychol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cpr.2015.08.004","article-title":"Response rates for CBT for anxiety disorders: need for standardized criteria.","volume":"42","author":"Loerinc","year":"2015","journal-title":"Clin Psychol Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1176\/ajp.153.10.1293","article-title":"Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders.","volume":"153","author":"Brown","year":"1996","journal-title":"Am J Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1037\/\/0021-843x.110.4.585","article-title":"Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample.","volume":"110","author":"Brown","year":"2001","journal-title":"J Abnorm Psychol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/da.23065","article-title":"Historic psychedelic drug trials and the treatment of anxiety disorders.","volume":"37","author":"Weston","year":"2020","journal-title":"Depress Anxiety."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD).","volume":"46","author":"Carhart-Harris","year":"2016","journal-title":"Psychol Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report.","volume":"37","author":"Os\u00f3rio","year":"2015","journal-title":"Braz J Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/jcp.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression.","volume":"36","author":"Sanches","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/s2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61169-x","article-title":"Effects of ayahuasca on mental health and quality of life in na\u00efve users: a longitudinal and cross-sectional study combination.","volume":"10","author":"Jim\u00e9nez-Garrido","year":"2020","journal-title":"Sci Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00213-019-05236-w","article-title":"A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.","volume":"236","author":"Uthaug","year":"2019","journal-title":"Psychopharmacology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s00213-018-4988-3","article-title":"Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution.","volume":"235","author":"Uthaug","year":"2018","journal-title":"Psychopharmacology."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin.","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","article-title":"Long-lasting subjective effects of LSD in normal subjects.","volume":"235","author":"Schmid","year":"2018","journal-title":"Psychopharmacology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.psych.55.090902.141913","article-title":"Personality development: stability and change.","volume":"56","author":"Caspi","year":"2005","journal-title":"Ann Rev Psychol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1037\/0021-843X.114.4.505","article-title":"Temperament as a unifying basis for personality and psychopathology.","volume":"114","author":"Clark","year":"2005","journal-title":"J Abnorm Psychol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/npp.2009.218","article-title":"Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding.","volume":"35","author":"Frokjaer","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev-clinpsy-032210-104540","article-title":"Personality and depression: explanatory models and review of the evidence.","volume":"7","author":"Klein","year":"2011","journal-title":"Ann Rev Clin Psychol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1521\/pedi.17.2.109.23986","article-title":"Personality and psychopathology: working toward the bigger picture.","volume":"17","author":"Krueger","year":"2003","journal-title":"J Pers Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cpr.2013.04.003","article-title":"Neuroticism and common mental disorders: meaning and utility of a complex relationship.","volume":"33","author":"Ormel","year":"2013","journal-title":"Clin Psychol Rev."},{"key":"B32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/2167702615618162","article-title":"Testing a hierarchical model of neuroticism and its cognitive facets: latent structure and prospective prediction of first onsets of anxiety and unipolar mood disorders during 3 years in late adolescence.","volume":"4","author":"Zinbarg","year":"2016","journal-title":"Clin Psychol Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1037\/bul0000088","article-title":"A systematic review of personality trait change through intervention.","volume":"143","author":"Roberts","year":"2017","journal-title":"Psychol Bull."},{"key":"B34","first-page":"p. 85","article-title":"Commentary: from kindling to conflagration: self-regulation and personality change.","author":"Roberts","year":"2006","journal-title":"Social Structures, Aging and Self Regulation in the Elderly."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042421","article-title":"Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study.","volume":"7","author":"Bouso","year":"2012","journal-title":"PLoS One."},{"key":"B36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.euroneuro.2015.01.008","article-title":"Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans.","volume":"25","author":"Bouso","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/acps.12904","article-title":"Effects of psilocybin therapy on personality structure.","volume":"138","author":"Erritzoe","year":"2018","journal-title":"Acta Psychiatr Scand."},{"key":"B38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/02791072.2020.1842569","article-title":"The psychedelic personality: personality structure and associations in a sample of psychedelics users.","volume":"53","author":"Johnstad","year":"2021","journal-title":"J Psychoactive Drugs."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.721537","article-title":"Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being.","volume":"12","author":"Kiraga","year":"2021","journal-title":"Front Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/02791072.2017.1312643","article-title":"Psychedelics, personality and political perspectives.","volume":"49","author":"Nour","year":"2017","journal-title":"J Psychoactive Drugs."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.749788","article-title":"Examining psychedelic-induced changes in social functioning and connectedness in a naturalistic online sample using the five-factor model of personality.","volume":"12","author":"Weiss","year":"2021","journal-title":"Front Psychol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.707057","article-title":"Examining the potential synergistic effects between mindfulness training and psychedelic-assisted therapy.","volume":"12","author":"Eleftheriou","year":"2021","journal-title":"Front Psychiatry."},{"key":"B43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","article-title":"A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.","volume":"33","author":"Madsen","year":"2020","journal-title":"Eur Neuropsychopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00213-019-05445-3","article-title":"Ayahuasca\u2019s \u201cafterglow\u201d: improved mindfulness and cognitive flexibility in ayahuasca drinkers.","volume":"237","author":"Murphy-Beiner","year":"2020","journal-title":"Psychopharmacology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1021\/acsptsci.1c00034","article-title":"Combining psychedelic and mindfulness interventions: synergies to inform clinical practice.","volume":"4","author":"Payne","year":"2021","journal-title":"ACS Pharmacol Transl Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00213-019-05414-w","article-title":"Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment.","volume":"237","author":"Uthaug","year":"2020","journal-title":"Psychopharmacology."},{"key":"B47","author":"Kabat-Zinn","year":"2009","journal-title":"Wherever you Go, There you are: Mindfulness Meditation in Everyday Life."},{"key":"B48","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1080\/00223980.2014.986430","article-title":"Worry and rumination in generalized anxiety disorder and obsessive compulsive disorder.","volume":"149","author":"Dar","year":"2015","journal-title":"J Psychol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1037\/a0018441","article-title":"Effects of mindfulness-based stress reduction (MBSR) on emotion regulation in social anxiety disorder.","volume":"10","author":"Goldin","year":"2010","journal-title":"Emotion."},{"key":"B50","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1023\/b:cotr.0000045557.15923.96","article-title":"The effects of mindfulness meditation on cognitive processes and affect in patients with past depression.","volume":"28","author":"Ramel","year":"2004","journal-title":"Cogn Ther Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.brat.2007.04.011","article-title":"Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder.","volume":"45","author":"Koszycki","year":"2007","journal-title":"Behav Res Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.","volume":"32","author":"Griffiths","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.","volume":"25","author":"MacLean","year":"2011","journal-title":"J Psychopharmacol."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression.","volume":"8","author":"Roseman","year":"2018","journal-title":"Front Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1192\/bjp.bp.116.194738","article-title":"Psychedelics and the science of self-experience.","volume":"210","author":"Nour","year":"2017","journal-title":"Br J Psychiatry."},{"key":"B56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr Drug Abuse Rev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00127-004-0797-6","article-title":"Anxiety and depression in the working population using the HAD scale\u2013psychometrics, prevalence and relationships with psychosocial work characteristics.","volume":"39","author":"Andrea","year":"2004","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"key":"B60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1037\/0096-3445.130.4.681","article-title":"Do threatening stimuli draw or hold visual attention in subclinical anxiety?","volume":"130","author":"Fox","year":"2001","journal-title":"J Exp Psychol Gen."},{"key":"B61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2478\/v10053-008-0100-6","article-title":"Dissociating effects of subclinical anxiety and depression on cognitive control.","volume":"8","author":"Ng","year":"2012","journal-title":"Adv Cogn Psychol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/0891988707317120","article-title":"Subclinical anxiety symptoms, sleep, and daytime dysfunction in older adults with primary insomnia.","volume":"21","author":"Spira","year":"2008","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1037\/0882-7974.18.3.622","article-title":"DSM-IV criteria for generalized anxiety disorder in older adults: distinguishing the worried from the well.","volume":"18","author":"Wetherell","year":"2003","journal-title":"Psychol Aging."},{"key":"B64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology."},{"key":"B65","year":"2015","journal-title":"Mushroom Tea Preparation."},{"key":"B66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.forsciint.2009.12.013","article-title":"Forensic analysis of hallucinogenic mushrooms and khat (Catha edulisForsk) using cation-exchange liquid chromatography.","volume":"195","author":"Laussmann","year":"2010","journal-title":"Forensic Sci Int."},{"key":"B67","author":"Spielberger","year":"1983","journal-title":"Manual for the State-Trait Anxiety Inventory STAI (Form Y)(\u201cSelf-Evaluation Questionnaire\u201d."},{"key":"B68","author":"Spielberger","year":"1989","journal-title":"State-Trait Anxiety Inventory: Bibliography."},{"key":"B69","first-page":"143","article-title":"Examining cut-off values for the state-trait anxiety inventory\/examinando los puntajes de corte para el inventario de ansiedad estado-rasgo.","volume":"24","author":"Ercan","year":"2015","journal-title":"Rev Argentina Cl\u00edn Psicol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/1073191105283504","article-title":"Using self-report assessment methods to explore facets of mindfulness.","volume":"13","author":"Baer","year":"2006","journal-title":"Assessment."},{"key":"B71","author":"John","year":"1991","journal-title":"The Big Five Inventory \u2013 Versions 4a and 54."},{"key":"B72","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1037\/\/0022-3514.75.3.729","article-title":"Los cinco grandes across cultures and ethnic groups: multitrait multimethod analyses of the big five in Spanish and English.","volume":"75","author":"Benet-Mart\u00ednez","year":"1998","journal-title":"J Pers Soc Psychol."},{"key":"B73","article-title":"The big-five trait taxonomy: history, measurement, and theoretical perspectives.","author":"John","year":"1999","journal-title":"Handbook of Personality: Theory and Research."},{"key":"B74","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology."},{"key":"B75","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00269","article-title":"Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).","volume":"10","author":"Nour","year":"2016","journal-title":"Front Hum Neurosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/da.20026","article-title":"Anxiety and depressive disorders and the five-factor model of personality: a higher- and lower-order personality trait investigation in a community sample.","volume":"20","author":"Bienvenu","year":"2004","journal-title":"Depress Anxiety."},{"key":"B78","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.psychres.2004.10.006","article-title":"Personality traits of patients with mood and anxiety disorders.","volume":"133","author":"Cuijpers","year":"2005","journal-title":"Psychiatry Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1207\/s15327752jpa8401_09","article-title":"Conducting and interpreting canonical correlation analysis in personality research: a user-friendly primer.","volume":"84","author":"Sherry","year":"2005","journal-title":"J Pers Assess."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2196\/25973","article-title":"Turn on, tune in, and drop out: predictors of attrition in a prospective observational cohort study on psychedelic use.","volume":"23","author":"H\u00fcbner","year":"2021","journal-title":"J Med Int Res."},{"key":"B81","author":"Leary","year":"2014","journal-title":"Introduction to Behavioral Research Methods."},{"key":"B82","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/02791072.2019.1580804","article-title":"Sub-Acute effects of psilocybin on empathy, creative thinking, and subjective well-being.","volume":"51","author":"Mason","year":"2019","journal-title":"J Psychoactive Drugs."},{"key":"B83","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1037\/0022-006X.63.3.408","article-title":"Comorbidity among anxiety and mood disorders: implications for treatment and DSM-IV.","volume":"63","author":"Brown","year":"1995","journal-title":"J Consult Clin Psychol."},{"key":"B84","year":"2017","journal-title":"Depression and Other Common Mental Disorders: Global Health Estimates. Rep. CC BY-NC-SA 3.0 IGO."},{"key":"B85","first-page":"p. 441","article-title":"Psycholytic therapy: statistics and indications.","author":"Mascher","year":"1967","journal-title":"Official Publication of the American College of Neuropsychopharmacology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00213-021-05817-8","article-title":"A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats.","volume":"238","author":"Uthaug","year":"2021","journal-title":"Psychopharmacology."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00881","article-title":"Modulation of social cognition via hallucinogens and \u201centactogens\u201d.","volume":"10","author":"Preller","year":"2019","journal-title":"Front Psychiatry."},{"key":"B88","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression.","volume":"57","author":"Watts","year":"2017","journal-title":"J Humanist Psychol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","article-title":"Psychedelic-Assisted Group Therapy: A Systematic Review","volume":"51","author":"Trope","year":"2019","journal-title":"J Psychoact Drugs"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine."},{"key":"B91","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.biopsych.2007.07.009","article-title":"Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder.","volume":"63","author":"Frokjaer","year":"2008","journal-title":"Biol Psychiatry."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0163-1","article-title":"Association between amygdala neurokinin-1 receptor availability and anxiety-related personality traits.","volume":"8","author":"Hoppe","year":"2018","journal-title":"Transl Psychiatry."},{"key":"B93","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1037\/a0020327","article-title":"Linking \u201cbig\u201d personality traits to anxiety, depressive, and substance use disorders: a meta-analysis.","volume":"136","author":"Kotov","year":"2010","journal-title":"Psychol Bull."},{"key":"B94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jpsychires.2021.03.002","article-title":"Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review.","volume":"137","author":"Romeo","year":"2021","journal-title":"J Psychiatr Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects.","volume":"4","author":"Olson","year":"2021","journal-title":"ACS Pharmacol Transl Sci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0022167817706884","article-title":"Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis.","volume":"57","author":"Belser","year":"2017","journal-title":"J Humanist Psychol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00005053-195812000-00006","article-title":"Psychotherapy with lysergic acid diethylamide.","volume":"127","author":"Eisner","year":"1958","journal-title":"J Nerv Ment Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00005053-195503000-00010","article-title":"Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy.","volume":"121","author":"Frederking","year":"1955","journal-title":"J Nerv Ment Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF01532413","article-title":"Mystical and archetypal experiences of terminal patients in DPT-assisted psychotherapy.","volume":"17","author":"Richards","year":"1978","journal-title":"J Relig Health."},{"key":"B100","first-page":"38","article-title":"Antecedents of mystical experience and dread in intensive meditation.","volume":"4","author":"Russ","year":"2017","journal-title":"Psychol Conscious Theor Res Pract."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00035","article-title":"The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization.","volume":"7","author":"Frecska","year":"2016","journal-title":"Front Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology.","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14700-6","article-title":"Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey.","volume":"7","author":"Lawn","year":"2017","journal-title":"Sci Rep."},{"key":"B104","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1556\/2054.2019.028","article-title":"The influence of context on ayahuasca experiences: an analysis of experience reports.","volume":"3","author":"Sapoznikow","year":"2019","journal-title":"J Psychedelic Stud."},{"key":"B105","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jclinepi.2004.05.006","article-title":"A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies.","volume":"58","author":"Chatfield","year":"2005","journal-title":"J Clin Epidemiol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1467-842x.2006.tb00849.x","article-title":"Attrition in longitudinal studies: who do you lose?","volume":"30","author":"Young","year":"2006","journal-title":"Aust N Z J Public Health."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.883869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:46:56Z","timestamp":1657154816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.883869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":107,"alternative-id":["10.3389\/fpsyt.2022.883869"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.883869","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.02.22271743","asserted-by":"object"}]},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"article-number":"883869"}}